Tumour necrosis factor alpha in severe congestive cardiac failure.
AUTOR(ES)
Dutka, D P
RESUMO
OBJECTIVE--To examine the concentration of circulating tumour necrosis factor alpha (TNF alpha) in patients with severe congestive heart failure (New York Heart Association class IV) during one year and to correlate changes in this cytokine with changes in plasma noradrenaline, plasma renin activity, and weight. DESIGN--A prospective study of the role of TNF alpha in severe chronic heart failure. Blood samples were collected at intervals of three months. SETTING--Medical research centre of a teaching hospital. PATIENTS--16 patients with chronic stable severe heart failure. INTERVENTIONS--Vasodilator treatment with captopril or flosequinan. MAIN OUTCOME MEASURES--Changes in TNF alpha and the correlation with changes in plasma noradrenaline, plasma renin activity, and weight during optimal medical treatment for one year. RESULTS--The mean concentration of TNF alpha was greater than the upper 95% confidence interval for healthy controls throughout the year of the study but there was considerable between and within patient variation. No correlation was seen between TNF alpha and plasma noradrenaline, plasma renin activity, or weight. CONCLUSIONS--The stimulus resulting in enhanced plasma concentrations of TNF alpha in congestive heart failure remains unclear and concentrations at any particular time were not prognostic.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1025274Documentos Relacionados
- Increased concentrations of tumour necrosis factor in "cachectic" patients with severe chronic heart failure.
- Haemochromatosis presenting as congestive cardiac failure.
- Controlled trial of enalapril in congestive cardiac failure.
- Intravenous captopril treatment in patients with severe cardiac failure.
- Haemodynamic effects of oral salbutamol alone and in combination with sublingual isosorbide dinitrate in patients with severe congestive cardiac failure.